MALAT1-MVP and MALAT1-NCBP3: In a prostate cancer mouse model, MALAT1 fusions, including MALAT1-MVP and MALAT1-NCBP3, were found to be implicated in resistance to second-generation antiandrogen cancer drugs (130). Here, MALAT1 is linked to prostate carcinoma.